Stockwatch: as pharma becomes the new biotech
This article was originally published in Scrip
Executive Summary
This week's explosion of second quarter earnings announcements thrust separate themes onto investors in pharmaceutical and biotechnology stocks. Some of those themes, like the patent cliff, have been a long time coming, some, like good second quarter earnings, seem to happen about the same time every year, and some may be a shorter-term cyclical effect.